PTPRN2 notes

2026-09-08 paired review

Selected accession A0A9L0T4W6; ordinary UniProt record is TrEMBL and cites genome sequencing/submission rather than a gene-specific functional experiment. Human evidence is summarized in the paired human investigation. Sequence comparison records the exact target gaps and transfer limits. The targeted Europe PMC search found no decisive gene-specific horse functional assay warranting a separate horse Edison investigation; general omics/association hits were not counted as mechanistic validation.

The 1996 cloning report states that recombinant IAR/PTPRN2 has phosphatase activity, but its abstract does not name the substrate. Later human cell work explicitly distinguishes lack of phosphoprotein-substrate activity from phosphoinositide phosphatase activity and tests the effect of a catalytic-domain mutant on migration and metastasis. Vesicle accumulation, insulin/neurotransmitter release, and membrane phosphoinositide regulation are not interchangeable with protein tyrosine dephosphorylation. Conversely, a biological-process annotation can describe regulation through another enzyme: losing intrinsic protein phosphatase activity alone does not refute all participation in protein dephosphorylation. The exact experimental annotation therefore remains unresolved while the inappropriate electronic intrinsic protein-phosphatase terms can be challenged.

Sources: PMID:8798755(https://pubmed.ncbi.nlm.nih.gov/8798755/), PMID:26620550(https://pubmed.ncbi.nlm.nih.gov/26620550/).

2026-10-20 — Full re-review, independent of the ProtNLM2 predictions

ProtNLM2 output was not opened or used. Deep research: just deep-research-falcon HORSE PTPRN2 --fallback perplexity-lite failed (Falcon "Failed to authenticate"; Perplexity HTTP 401 insufficient quota), so no horse deep-research file exists. The review uses primary literature cached in publications/.

Identity of the benchmark accession (alternative gene model)

compare_horse_models_rereview.py produced RESULTS-rereview.md and results-rereview.json. Findings:

Evolutionary basis for transfer

Annotation decisions

Relative to review next

A0A9L0T4W6 is a non-canonical alternative gene model. The canonical product of the same horse gene, A0A9L0RAE3, has no review. Suggested folder: genes/HORSE/PTPRN2__A0A9L0RAE3. The PANTHER family review (interpro/panther/PTHR46106) also places the horse protein in SF5, so there is no subfamily disagreement. But it uses the non-canonical A0A9L0T4W6 as the horse representative and repeats the "989-1003 deletion" description. No module in modules/ includes PTPRN2; modules/beta_cell_glucose_stimulated_insulin_secretion.yaml is the closest pathway context.

2026-10-21 — NEW rows withdrawn from the alternative gene model (PR #5303 review)

The re-review had proposed NEW rows (GO:0051046) on this benchmark accession because GOA propagates the
gene's annotations, including PAINT IBA rows, to one representative product per gene and not to
alternative transcript models. The same terms are already annotated in GOA on the canonical horse
product of this gene (PTPRN2__A0A9L0RAE3, reviewed in genes/HORSE/PTPRN2__A0A9L0RAE3/). Filling that propagation
convention on a second product of the same gene is not a curation gap, so the rows were withdrawn
for consistency across the cohort. The gene-level function is unchanged and is recorded on the
canonical product's review; this file's description and core functions still describe it.